Syquant Capital Sas Genfit S.A. Call Options Transaction History
Syquant Capital Sas
- $9.93 Million
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GNFT
# of Institutions
7Shares Held
76.8KCall Options Held
0Put Options Held
0-
Israel Englander Millennium Management LLC | New York, Ny29.7KShares$129,5660.0% of portfolio
-
Morgan Stanley New York, NY28.5KShares$124,1030.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il16.8KShares$73,3910.0% of portfolio
-
Optiver Holding B.V. Amsterdam, P7963Shares$4,1980.0% of portfolio
-
Rhumbline Advisers Boston, MA678Shares$2,9560.0% of portfolio
About Genfit S.A.
- Ticker GNFT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,815,500
- Market Cap $217M
- Description
- Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...